Related Experiment Videos
Immune neuropathies in childhood
1Emory University School of Medicine, Atlanta, GA 30322, USA.
Bailliere'S Clinical Neurology
|March 1, 1996
Summary
Immune-mediated disorders cause many childhood peripheral neuropathies, with Guillain-Barré syndrome (GBS) being the most common. While treatments like plasmapheresis show promise for pediatric GBS, more research is needed for other immune neuropathies.
Area of Science:
- Pediatric Neurology
- Immunology
- Demyelinating Diseases
Background:
- Immune-mediated disorders are a leading cause of peripheral neuropathies in children, unlike in older populations.
- Guillain-Barré syndrome (GBS) is the most frequent diagnosis, accounting for 25% of pediatric sensorimotor neuropathies.
- Chronic inflammatory demyelinating polyneuropathy (CIDP) is the second most common cause of chronic sensorimotor neuropathy in children.
Purpose of the Study:
- To review the epidemiology and clinical features of immune-mediated peripheral neuropathies in children.
- To discuss current treatment modalities and prognosis for pediatric GBS and CIDP.
- To highlight the relative rarity of other immune-mediated neuropathies and HIV-associated neuropathies in this age group.
Main Methods:
- Retrospective analysis of pediatric cases with peripheral neuropathy.
- Review of clinical presentations, diagnostic entities, and treatment outcomes.
- Comparison of pediatric findings with adult populations.
Main Results:
- GBS is the most common immune-mediated neuropathy in children, with a generally better prognosis than in adults.
- Plasmapheresis appears effective for GBS recovery in children, though data is limited.
- CIDP presents variably in children and has a good prognosis, but some cases result in significant disability or side effects.
Conclusions:
- Immune-mediated neuropathies, particularly GBS and CIDP, are significant causes of peripheral nerve disorders in children.
- Treatment strategies for pediatric GBS are evolving, with plasmapheresis showing potential.
- Further research is needed to establish optimal management for pediatric immune-mediated neuropathies, especially regarding intravenous immunoglobulin (IVIG) for GBS.